Inflammation in multiple sclerosis: The good, the bad, and the complex

Gianvito Martino, Luciano Adorini, Peter Rieckmann, Jan Hillert, Boris Kallmann, Giancarlo Comi, Massimo Filippi

Research output: Contribution to journalArticle

Abstract

Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. We argue that the use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Precise identification of the inflammatory pathways to be targeted in the different phases of the disease and the timing of such interventions are therefore crucial.

Original languageEnglish
Pages (from-to)499-509
Number of pages11
JournalThe Lancet Neurology
Volume1
Issue number8
DOIs
Publication statusPublished - Aug 1 2002

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this